John Capodanno is a Partner at DGA Group and is based in the New York office.

With more than 25 years of corporate communications experience across a broad range of healthcare and life sciences companies, Mr. Capodanno’s clients include large cap multinational pharmaceutical companies, small and mid-size biotech and medical device companies, as well as large health insurers and regional hospital systems. Providing communications strategy and counsel to CEOs, CFOs, and heads of Communications, Marketing and HR has been a cornerstone of his career. His extensive experience includes advising companies on communicating business strategy, driving valuation, and managing and mitigating issues to provide them with the freedom to operate in a highly regulated and competitive marketplace.

Mr. Capodanno has a long track record of leading and building programs for some of the world’s largest pharmaceutical and healthcare companies around the world. His experience includes an award-winning program for a $65bn+ healthcare merger; serving as an expert on behalf of a medical device company as claimant and counter-responder in litigation around the role of communications best practices for clinical trials; and, conceptualizing and implementing communications efforts for the Foundation of a Fortune 50 company, which won a top award from GBCHealth.

Mr. Capodanno has also built and grown teams that can collaborate and thrive in a highly competitive environment. Prior to joining DGA, he was President at Real Chemistry, leading their Corporate Communications Practice, including Investor Relations, Public Affairs and Corporate Strategy.  Prior to that, he led the Healthcare & Life Sciences sector in the Americas at FTI Consulting.